. . "S" . "Nov\u00E1kov\u00E1, Jana" . "Statiny jsou l\u00E1tky blokuj\u00EDc\u00ED biosynt\u00E9zu cholesterolu inhibic\u00ED kl\u00ED\u010Dov\u00E9ho enzymu jeho metabolick\u00E9 dr\u00E1hy, 2-hydroxy-2-metylglutaryl-CoA (HMG-CoA) redukt\u00E1zy. \u0158ada velk\u00FDch klinick\u00FDch studi\u00ED prok\u00E1zala u statin\u016F dobrou toleranci, relativn\u00ED bezpe\u010Dnost a p\u0159edev\u0161\u00EDm \u00FA\u010Dinnost, kter\u00E1 se projevila sn\u00ED\u017Een\u00EDm kardiovaskul\u00E1rn\u00ED morbidity a mortality u pacient\u016F s hypercholesterol\u00E9mi\u00ED, kde jsou tato hypolipidemika prim\u00E1rn\u011B indikov\u00E1na. Preklinick\u00FD v\u00FDzkum za posledn\u00EDch 5 let dok\u00E1zal, \u017Ee statiny vykazuj\u00ED v bun\u011B\u010Dn\u00FDch syst\u00E9mech pleiotropn\u00ED efekt. Ten je d\u016Fsledkem jejich p\u0159\u00EDm\u00E9ho i nep\u0159\u00EDm\u00E9ho p\u016Fsoben\u00ED na regula\u010Dn\u00ED mechanizmy bun\u011B\u010Dn\u00E9ho cyklu, diferenciace, apopt\u00F3zy a na \u0159adu dal\u0161\u00EDch fyziologick\u00FDch d\u011Bj\u016F, kter\u00E9 hraj\u00ED d\u016Fle\u017Eitou roli i v procesu onkogeneze. Abychom v\u0161ak byli schopni zodpov\u011Bdn\u011B posoudit skute\u010Dn\u00FD p\u0159\u00EDnos statin\u016F pro chemoprevenci nebo pro terapii n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED, bude nezbytn\u00E9 p\u0159\u00EDmo za t\u00EDmto \u00FA\u010Delem uskute\u010Dnit v\u00EDce prospektivn\u00EDch klinick\u00FDch studi\u00ED."@cs . . "1212-7973" . "Klinick\u00E1 farmakologie a farmacie" . "Statiny v onkologii"@cs . "544526" . "Vysko\u010Dil, Ji\u0159\u00ED" . "14110" . . "Statiny v onkologii" . "[D7A693AF7614]" . "RIV/00216224:14110/05:00031188" . . . "statins; HMG-CoA; human tumours; oncogenesis"@en . "Statiny v onkologii" . . . "Statiny v onkologii"@cs . "Statins in incology"@en . . "3"^^ . . "3"^^ . . "Statins in incology"@en . "19" . "5"^^ . . "Statins are the most frequently used hypolipidaemic drugs, lowering cholesterol by inhibition of the key enzyme of cholesterol biosynthesis, the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA). This enzyme is responsible for the production of mevalonic acid, the main precursor of cholesterol synthesis. A number of clinical trials show that statins are well tolerated, relatively safe and very efficient drugs that significantly decrease cardiovascular morbidity and mortality in patients suffering from hypercholesterolaemia, which is the main indication for prescription of statins. Within the last five years, the results of preclinical research have proven the pleiotropic effects of statins in cell systems which are due to their direct or indirect influence on regulation of mechanisms such as the cell cycle, differentiation and apoptosis. These physiological processes play an important role in oncogenesis and, therefore, the role of statins in oncology is being seriously discussed."@en . "Statiny jsou l\u00E1tky blokuj\u00EDc\u00ED biosynt\u00E9zu cholesterolu inhibic\u00ED kl\u00ED\u010Dov\u00E9ho enzymu jeho metabolick\u00E9 dr\u00E1hy, 2-hydroxy-2-metylglutaryl-CoA (HMG-CoA) redukt\u00E1zy. \u0158ada velk\u00FDch klinick\u00FDch studi\u00ED prok\u00E1zala u statin\u016F dobrou toleranci, relativn\u00ED bezpe\u010Dnost a p\u0159edev\u0161\u00EDm \u00FA\u010Dinnost, kter\u00E1 se projevila sn\u00ED\u017Een\u00EDm kardiovaskul\u00E1rn\u00ED morbidity a mortality u pacient\u016F s hypercholesterol\u00E9mi\u00ED, kde jsou tato hypolipidemika prim\u00E1rn\u011B indikov\u00E1na. Preklinick\u00FD v\u00FDzkum za posledn\u00EDch 5 let dok\u00E1zal, \u017Ee statiny vykazuj\u00ED v bun\u011B\u010Dn\u00FDch syst\u00E9mech pleiotropn\u00ED efekt. Ten je d\u016Fsledkem jejich p\u0159\u00EDm\u00E9ho i nep\u0159\u00EDm\u00E9ho p\u016Fsoben\u00ED na regula\u010Dn\u00ED mechanizmy bun\u011B\u010Dn\u00E9ho cyklu, diferenciace, apopt\u00F3zy a na \u0159adu dal\u0161\u00EDch fyziologick\u00FDch d\u011Bj\u016F, kter\u00E9 hraj\u00ED d\u016Fle\u017Eitou roli i v procesu onkogeneze. Abychom v\u0161ak byli schopni zodpov\u011Bdn\u011B posoudit skute\u010Dn\u00FD p\u0159\u00EDnos statin\u016F pro chemoprevenci nebo pro terapii n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED, bude nezbytn\u00E9 p\u0159\u00EDmo za t\u00EDmto \u00FA\u010Delem uskute\u010Dnit v\u00EDce prospektivn\u00EDch klinick\u00FDch studi\u00ED." . "Svoboda, Marek" . . . . "RIV/00216224:14110/05:00031188!RIV10-MSM-14110___" . "CZ - \u010Cesk\u00E1 republika" . "3" . . .